Jun 26 2023 |
et al., NCT04439071 | Evaluation of the Efficacy and Safety of PTC299 in Hospitalized Subjects With COVID-19 (FITE19) |
| 132% higher mortality (p=0.16) and 47% higher ventilation (p=0.31). RCT 189 hospitalized patients showing higher mortality with emvododstat (PTC299), without statistical significance. | ||
Jan 31 2021 |
et al., Virus Research, doi:10.1016/j.virusres.2020.198246 | The DHODH inhibitor PTC299 arrests SARS-CoV-2 replication and suppresses induction of inflammatory cytokines |
| In Vitro study showing that PTC299, a dihydroorotate dehydrogenase inhibitor, inhibited SARS-CoV-2 replication with an EC50 of 1.96-31.6 nM and reduced inflammatory cytokine production. PTC299 had broad antiviral activity against HCV, pol.. | ||
Please send us corrections, updates, or comments.
c19early involves the extraction of 100,000+ datapoints from
thousands of papers. Community updates
help ensure high accuracy.
Treatments and other interventions are complementary.
All practical, effective, and safe
means should be used based on risk/benefit analysis.
No treatment or intervention is 100% available and effective for all current
and future variants.
We do not provide medical advice. Before taking any medication,
consult a qualified physician who can provide personalized advice and details
of risks and benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.